The outlook of companies tied to Sildenafil's past presents a complex investment scenario . While the initial boom generated substantial profits , generic alternatives have significantly diminished sales . Investing in connected pharmaceutical businesses now requires a discerning assessment of intellectual property protection , evolving patient shi